Showing 3621-3630 of 5773 results for "".
- Nicox Outlines Future Development and Partnering Plans for NCX 470https://modernod.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. “Our market research&nbs
- Iveric Bio Submits First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophyhttps://modernod.com/news/iveric-bio-submits-first-part-of-nda-for-rolling-review-of-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy/2481227/Iveric bio announced that it has submitted to the FDA the first part of its new drug application (NDA) for rolling review of avacincaptad pegol (ACP, also known as Zimura) a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to age-related m
- Medicontur Launches Bi-Flex Elon Nondiffractive EDOF IOLhttps://modernod.com/news/medicontur-launches-bi-flex-elon-nondiffractive-edof-iol/2481224/Medicontur announced the launch of the Bi-Flex Elon Nondiffractive EDOF IOL. The Elon, which was launched on September 6, features proprietary Wavefront Linking technology that is designed to create a true elongated focus with minimal optical disturbances. This non-d
- Verana Health to Present Findings of Studies Using AAO IRIS Registry Data to Advance Insights into Real World Outcomes in Treating AMDhttps://modernod.com/news/verana-health-to-present-findings-of-studies-using-aao-iris-registry-data-to-advance-insights-into-real-world-outcomes-in-treating-amd/2481222/During The Retina Society’s 55th Annual Scientific Meeting Nov. 2-5, Verana Health will present findings on two studies that utilize curated real-world data (RWD) from the American Academy of Ophthalmology (Academy)
- Aramis Biosciences Completes Enrollment of its Phase 2 Clinical Trial Evaluating A197 for the Treatment of Dry Eye Diseasehttps://modernod.com/news/aramis-biosciences-completes-enrollment-of-its-phase-2-clinical-trial-evaluating-a197-for-the-treatment-of-dry-eye-disease/2481219/Aramis Biosciences announced the completion of enrollment in its phase 2 proof of concept clinical trial evaluating A197, a novel, first-in-class, topical immunomodulatory agent for the treatment of dry eye disease. “We are very pleased to have completed the enrollment of our phas
- Replay Launches Its First HSV Gene Therapy Company, Eudora, Focused on Retinal Eye Diseasehttps://modernod.com/news/replay-launches-its-first-hsv-gene-therapy-company-eudora-focused-on-retinal-eye-disease/2481216/Replay announced the launch of Eudora, an HSV gene therapy company targeting genetic retinal diseases. It is the first of Replay’s product companies to leverage its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV. Eudora’s co-founders, Professors Joe Glor
- Topcon Offers Maestro2 OCT Certification Coursehttps://modernod.com/news/topcon-offers-maestro2-oct-certification-course/2481213/Topcon Healthcare has announced the new
- BioTissue Completes Name Changehttps://modernod.com/news/biotissue-completes-name-change/2481211/BioTissue Holdings announced the completion of its name change from TissueTech. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Pursuant to the name change, the former Tis
- Heru Makes Appointments to Its Executive Leadership Teamhttps://modernod.com/news/heru-makes-appointments-to-its-executive-leadership-team/2481210/Heru announced several key executive appointments across its leadership team and board of directors designed to strengthen the company’s commercial operation and support its next phase of growth. Fred Drasner has been appointed as Heru’s Chairman of the Board of
- Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470https://modernod.com/news/nicox-reports-achieving-primary-objective-in-mont-blanc-the-first-phase-3-glaucoma-trial-for-ncx-470/2481209/Nicox SA announced that once daily dosing of NCX 470 0.1% met the primary objective of noninferiority in lowering IOP compared to the standard of care, latanoprost 0.005%, in the 691-patient Mont Blanc phase 3 clinical trial in patients with open-angle glaucoma or ocular hypertension.</